Cost-Effectiveness of Salt Substitute and Salt Supply Restriction in Eldercare Facilities
Authors: Xiaozhen Lai, Yifang Yuan, Hongxia Wang, Ruijuan Zhang, Qianku Qiao, Xiangxian Feng, Aoming Jin, Huijuan Li, Jiayu Li, Lei Si, Pei Gao, Stephen Jan, Hai Fang, Yangfeng Wu, Junshi Chen, Bruce Neal, Darwin Labarthe, Paul Elliott, Minghui Zhao, Wenyi Niu, Runlin Gao, Xiaofeng Liang, Yong Huo, Changsheng Ma, Yihong Sun, Xun Tang, Wei Zhao, Zhun Sui, Jinwei Wang, Xingshan Zhao, Xin Du, Weiping Sun, Gaoqiang Xie, Fengzhi Wang, Shulan Zhu, Lin Feng, Jianhui Yuan, Peifen Duan, Yanbo Han, Xiaorui Cui, Decheng Li, Peng Gao, La’e Cao, Lili Cheng, Lili Zhang, Lidong JI, Wenjie Yu, Hui Zhang, Sujuan Wang, Ran Zhuo, Jing Hang, Li Yang, Xiaoqin QI, Senke Hu, Yanxi Wang, Yuqi Wang, Yang Shen, Huan Chang
Journal: JAMA Network Open (2024)

Importance Salt substitution has been reported to be a cost-saving sodium reduction strategy that has not yet been replicated in different contexts. Objective To estimate the cost-effectiveness of sodium reduction strategies within the DECIDE-Salt trial. Design, Setting, and Participants The DECIDE-Salt trial cluster randomized in a 1:1:1:1 ratio 48 eldercare facilities in China into 4 groups for evaluation of 2 sodium reduction strategies for 2 years: 1 with both strategies, 2 with either strategy, and 1 with neither strategy. The trial was conducted from September 25, 2017, through October 24, 2020. Interventions The 2 intervention strategies were replacing regular salt with salt substitute and progressively restricting salt supply to kitchens. Main Outcomes and Measures The main outcomes included per-participant costs of intervention implementation and medical treatments for hypertension and major adverse cardiovascular events (MACEs) against mean reductions in systolic blood pressure, hypertension prevalence, MACE incidence, and mortality. The incremental cost-utility ratio was then assessed as the additional mean cost per quality-adjusted life-year gained. Analyses were conducted separately for each strategy, comparing groups assigned and not assigned the test strategy. Disease outcomes followed the intention-to-treat principle and adopted different models as appropriate. One-way and probabilistic sensitivity analyses were conducted to explore uncertainty, and data analyses were performed between August 13, 2022, and April 5, 2023. Results A total of 1612 participants (1230 males [76.3%]) with a mean (SD) age of 71.0 (9.5) years were enrolled. Replacing regular salt with salt substitute reduced mean systolic blood pressure by 7.14 (95% CI, 3.79-10.48) mm Hg, hypertension prevalence by 5.09 (95% CI, 0.37-9.80) percentage points, and cumulative MACEs by 2.27 (95% CI, 0.09-4.45) percentage points. At the end of the 2-year intervention, the mean cost was $25.95 less for the salt substitute group than the regular salt group due to substantial savings in health care costs for MACEs (mean [SD], $72.88 [$9.11] vs $111.18 [$13.90], respectively). Sensitivity analysis showed robust cost savings. By contrast, the salt restriction strategy did not show significant results. If the salt substitution strategy were rolled out to all eldercare facilities in China, 48 101 MACEs and 107 857 hypertension cases were estimated to be averted and $54 982 278 saved in the first 2 years. Conclusions and Relevance The findings of this cluster randomized clinical trial indicate that salt substitution may be a cost-saving strategy for hypertension control and cardiovascular disease prevention for residents of eldercare facilities in China. The substantial health benefit savings in preventing MACEs and moderate operating costs offer strong evidence to support the Chinese government and other countries in planning or implementing sodium intake reduction and salt substitute campaigns. Trial Registration ClinicalTrials.gov Identifier: NCT03290716